Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

Phase 3

Terminated

• Conditions: Diffuse Diabetic Macular Edema
• Interventions: Procedure: Bevacizumab + pars plana vitrectomy

• Registration Number: NCT00571142
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Primary Completion: 2007-11
• Study First Submitted: 2007-12-07
• Study First Submitted QC: 2007-12-07
• Study First Posted: 2007-12-11
• Study Completion: 2008-02
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Older than 25 yo
• Diffuse diabetic macular edema with or without previous treatment

Exclusion Criteria

• Another retinal disease
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
2	Bevacizumab + pars plana vitrectomy	Without renal disease
1	Bevacizumab + pars plana vitrectomy	Renal disease

Primary Outcome Measures

Name	Time	Method
Retinal thickness	3 months

Secondary Outcome Measures

Name	Time	Method
Visual acuity	3 months

Trial Locations

Locations (1)

Asociacion para Evitar la Ceguera en Mexico I.A.P.; 🇲🇽 Mexico, Mexico